CRMD241018P9000
- 0.60
- -0.10-14.29%
CorMedix Newsroom
Hedge Funds Pile Into Healthcare Stocks Amid Dip, Goldman Sachs Says
CorMedix Inc. (NASDAQ:CRMD): When Will It Breakeven?
CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States
CorMedix Inc. to Present at the Cantor Global Healthcare Conference
CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
Buy Rating on Cormedix Affirmed Amidst DefenCath's Strong Market Entry and Growth Prospects
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
JMP Securities analyst Jason Butler maintains $CorMedix(CRMD.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 37.4% and a
CorMedix Has Entered Into A Multi-Year Commercial Supply Contract With A Global Healthcare Company For The Supply Of DefenCath To Its Facilities In The U.S.
Express News | CorMedix Inc - Defencath Shipments Under Agreement to Begin in Q4
Express News | CorMedix Inc - Expects to Initially Target Utilization of Defencath in up to 4,000 Patients Nationally
Express News | CorMedix Inc. Announces New Commercial Agreement
CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Rodman & Renshaw Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $13
Rodman & Renshaw analyst Brandon Folkes initiates coverage on $CorMedix(CRMD.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 35.0
CorMedix Price Target Announced at $13.00/Share by Rodman & Renshaw
CorMedix Initiated at Buy by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $13
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's Is How to Trade
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Truist Financial analyst Les Sulewski maintains $CorMedix(CRMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of 2.7% over the
CorMedix Inc.'s (NASDAQ:CRMD) Profit Outlook